Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty.
OBJECTIVE
We tested the hypothesis that reduced acute platelet deposition after angioplasty results in reduced late neointimal proliferation.


BACKGROUND
Platelet-mediated mechanisms contribute to smooth muscle cell proliferation and migration.


METHODS
Indium-111-labeled platelets were injected 16 h before coronary stent angioplasty in 10 Göttinger minipigs: group 1 (n = 5) = heparin (100-U/kg bolus) before angioplasty; group 2 (n = 5) = recombinant hirudin (CGP 39393, 1.0-mg/kg body weight bolus intravenously), followed by subcutaneous doses of 6 to 10 mg/kg every 8 h. Furthermore, stent angioplasty was performed in coronary arteries of 16 minipigs: group 3 (n = 5, nine stents) = 100 U/kg heparin only; group 4 (n = 5, 10 stents) = 1-mg/kg bolus hirudin before and 45 min after angioplasty; group 5 (n = 6, 11 stents) = hirudin (1-mg/kg intravenous bolus) before and 45 min after angioplasty, followed by 6 to 10 mg/kg subcutaneously every 8 h.


RESULTS
In segments with deep arterial injury, the number of platelets/angioplasty segment in group 2 after 72 h (mean 21, range 9.7 to 39.7 x 10(6)) was significantly less than that in group 1 (mean 375, range 72 to 787 x 10(6)). Morphometric analysis after 4 weeks showed no difference between groups in degree of vessel wall injury. Mean (+/- SD) neointimal thickness was 0.70 +/- 0.06 mm in group 3 and was significantly reduced in both group 4 (0.46 +/- 0.11 mm) and group 5 (0.48 +/- 0.21 mm).


CONCLUSIONS
The direct thrombin inhibitor hirudin significantly reduces platelet deposition up to 72 h after coronary stent angioplasty. A hirudin bolus alone as well as continued subcutaneous administration for 14 days substantially reduced neointimal proliferation compared with heparin 4 weeks after coronary stent angioplasty in minipigs.
Unterberg
C
C
Department of Cardiology, University of Göttingen, Germany.
Sandrock
D
D
Nebendahl
K
K
Buchwald
A B
AB
D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D001792:Blood Platelets / Q000473:pathology; D002455:Cell Division; D003331:Coronary Vessels / Q000378:metabolism / Q000473:pathology; D005337:Fibrin / Q000378:metabolism; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins / Q000627:therapeutic use; D015607:Stents; D013552:Swine; D013556:Swine, Miniature; D013927:Thrombosis / Q000473:pathology / Q000517:prevention & control*; D017539:Tunica Intima / Q000473:pathology*
D000925:Anticoagulants; D006629:Hirudins; D011994:Recombinant Proteins; D005337:Fibrin; D006493:Heparin; C060225:desirudin